Evidence map›Paper›PMID 39717059›Full record

ArticleDrugs in context2024

Good scientific practice of using worldwide post-marketing surveillance data to ensure safety with HA

Hema Sundaram, Beatriz Molina, Editta Buttura da Prato, Gabriel Siquier-Dameto, Michela Zazzaron, Clara Cigni, Franco Grimolizzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs in context, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hema SundaramPrivate Practice, Rockville, Maryland; Private Practice, Fairfax, Virginia, USA.
Beatriz MolinaMedikas Clinic, Somerset, Bristol, UK.
Editta Buttura da PratoPrivate Practice, Verona, Italy.
Gabriel Siquier-DametoDameto Clinics International, Campanet, Spain.
Michela ZazzaronPrivate Practice, Roncade, Treviso, Italy.
Clara CigniIBSA Farmaceutici Italia Srl, Lodi, Italy.
Franco GrimolizziIBSA Farmaceutici Italia Srl, Lodi, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Aliaxin fillers (HA Methods: Post-marketing surveillance was registered by the manufacturer from January 2018 to September 2023. During this period, product complaints were globally gathered from healthcare practitioners and consumers, relating to technical issues or safety and product-related adverse events. Results: No discernible trend or substantial escalation in AEs across the entire product range were observed during the surveillance period ( Conclusion: The analysed data further support and confirm the high safety profile of the HA

Indexed as

BDDE cross-linked dermal fillerfiller complicationshyaluronic acidinjectable safetypost-marketing surveillancesafety

Identifiers

PMID39717059
PMCPMC11666269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.